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The Scholarly Publishing Scene — Create or Buy?
Column Editor: Myer Kutz (President, Myer Kutz Associates, Inc.) <myerkutz@aol.com>

B

ack in the day (there I go again, but
bear with me), when I was an executive
running the STM portion of a publishing
house — Wiley, to be specific — I didn’t get
myself involved in making an acquisition of
another publisher, or a list of books or journals
from another publisher. Maybe it was my
engineering background. I was always more
excited by creating something new, rather than
buying what someone else had created.
There can be financial advantages, of
course, to buying rather than creating. A journals list can be especially attractive because
you can combine back office operations, thereby reducing expenses, while you add revenue.
A lure of acquiring a books list is the author
contracts for titles that haven’t been published
yet. Think about efficient use of resources: for
the time being, at least, you can get along with
the same number of editors while increasing
the number of titles in the pipeline.
Despite my predilection for creating rather
than buying, I didn’t labor under any absurd
presumption that I could, all by myself, corner
the market on dreaming up new titles for books,
journals or any other type of STM publication.
I had enough experience as an acquisitions editor earlier in my publishing career to know that
potential authors would be the source of many
of the ideas for successful new titles. And it
was my team of editorial managers and editors
who would query academics and practitioners
about what books and other publications upper
level students and practitioners needed in their
disciplines.
The team, comprised of a couple of dozen
seasoned professionals, was adept at finding
and signing up authors for new book projects
and seeing to it that they were actually delivered and published. At the same time, I recognized that if I were to quickly grow the business segment I was responsible for, I needed
subscription-based products that would make a
bigger impact than typical journals, which tend
to add new subscribers rather slowly.
As it happened, I got lucky. A young woman named Sarah Greene, who had been a life
sciences editor at Macmillan, walked into my
office one day with a subscription project called
Current Protocols in Molecular Biology. The
authors, who had appointments at Harvard
Medical School and Massachusetts General
Hospital, had convinced Sarah that because
their field was so dynamic, an ordinary bound
book would be inadequate. It would be out of
date before it went to press. Loose-leaf publishing was the only way to go, they told her.
(This was in the pre-CD-ROM and subsequent
Internet days.)
When Sarah’s bosses at Macmillan told
her that loose-leaf publishing was fraught with
fulfillment problems, she quit her job and struck
out on her own. Sarah convinced me that the
molecular biology field was indeed exploding
and that a subscription publication would best
meet the needs of experimenters and researchers
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in search of the latest and most successful experimental techniques. It did turn out that Sarah’s
Macmillan bosses had been right about looseleaf fulfillment costs. But I was right to accept
her characterization of the molecular biology
field, and we got 10,000 subscribers by the end
of the first year. It came as no surprise to me that
because of the growing pains associated with a
fledgling fulfillment operation I had to defend
the project against senior management’s condemnation. But I did prevail, and the molecular
biology project became the first of an extensive
series of protocols publications.
I treated Sarah as a business partner sharing
in profits, not as an author receiving royalties
based on a percentage of net sales. I called
our partnership a “joint venture.” It was the
first of five joint ventures that I developed
over the next several
years. (The second
one, which had lovely
side benefits, was with
a Paris-based company.
We published the Crop
Protection Chemical
Reference, an annual directory in which manufacturers paid to have their products listed.)
Publishers Weekly got wind of these activities
and published a full-page article about them.
When I showed the article to my boss, he
scoffed at it. I didn’t catch on right away, but
the handwriting was on the wall in caps, and
my days at that position were numbered indeed.
Truth be told, while I was running STM
publishing at Wiley, I did look into acquiring
a few book publishers, including CRC Press
(when it was rather small and was reliant
on sales of the Handbook of Chemistry and
Physics, formerly known as the Chemical and
Rubber Company Handbook of Chemistry and
Physics), Birkhauser (then an independent
Swiss publisher with an office in the Boston
area), and a small fiefdom called Noyes Publications, run by a crusty old gent named Bob
Noyes. He ran the business out of a large
building he owned (it was a valuable piece of
real estate) in downtown Saddle River, NJ. (I
can still remember a framed photo he displayed
of his wife with Dick Nixon.) The list included
a mixture of original titles and reprinted government reports. Annual sales were a couple
of million dollars.
After I left Wiley and established a consulting practice, I became interested in acquisitions, for the simple reason that brokering
them could be lucrative. But I didn’t focus on
them until one day in the latter 1990s when Bob
Noyes phoned to say that he wanted to sell his
business. It was now half the size it had been
when I’d last looked at it; the government reprints part had withered away. Still, I thought I
could find a buyer, and I prepared a prospectus.
Every so often, I would drive out from my
Manhattan apartment to New Jersey to discuss
with Bob my lack of progress in finding a
buyer for his business. He’d buy me lunch and

then I would get lost in northern New Jersey’s
winding residential streets as I tried to make my
way north to spend weekends with my future
wife, who lived near Albany. Throughout the
1990s, I was going to the Frankfurt Book
Fair to drum up consulting business. I had
no success, until a friend introduced me to
Norman Rentrop, a German publisher, and I
picked up a nice consulting assignment. On
that same trip, I came across the stand of a little
company called William Andrew, which was
looking to increase its sales.
Long story short, I brokered a deal between
Bob Noyes and the two young guys who ran
William Andrew — Bill Woishnis, who had
started the company with plastics data books
that he put together himself, and Chris Forbes,
who was originally Canadian and, I gathered,
had bought into the
company. Bob Noyes
suffered from a case
of cold feet in the days
right before the closing, but the acquisition
did come together at a
price that satisfied both sides and provided me
with a nice fee.
For the next year or two, while Bill and
Chris kept the Noyes operation in New Jersey,
I helped build up their publishing business. I
also spent time at their main operation in Norwich, NY, near Oneonta, and got to know them
better — Bill especially, who had a young son.
Over the next eight to ten years, I met up with
both Bill and Chris fairly regularly, although
more often with Bill. He and I worked together
on the idea for the first of two engineering
handbooks I published with William Andrew.
We would have dinner together during PSP
Annual Conferences in February.
I watched from afar when Bill and Chris
developed Knovel, their online book service.
One of the last times I saw Bill was in Albany.
(I’d decided, during the days when Bob Noyes
seemed to be pulling back from selling his
company and my payday seemed to be evaporating, to move up there to join my future wife
full time). Bill introduced me to the Elsevier
executive who was in charge of the William
Andrew list, which Elsevier had purchased. (I
now publish three handbooks with Elsevier.)
Another time, I drove out to Oneonta for lunch
with Bill to talk about the circumstances of his
having left Knovel, which was now solely in
Chris’s hands. Then one day someone called
me to tell me that Bill had been waiting for his
son to be finished with an appointment in Oneonta and had been walking in a park, when he
suddenly collapsed and died of a heart attack.
He was only 50.
In the end, Elsevier acquired Knovel, in
addition to the William Andrew list. With
ScienceDirect, into which they’d poured over a
hundred and seventy million dollars, they now
had, I thought, the best of both possible create
or buy worlds.
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